We are about to have more data about human biology than ever before. That is changing how medicines are invented, how they are prescribed, and how patients and physicians interact with unprecedented speed. Medicine has gone from faxes to electronic health records to large language models, from mouse models to organs on a chip to gene editing.
But the biggest — and toughest — change will come when artificial intelligence and other technologies transform the budget-straining process of turning big ideas into actual drugs, upending the economics of one of the world’s most challenging businesses.
Here, STAT will ask the perennial, trenchant questions among those in the field: Are we there yet? And how much longer? This extends to an array of transformative new technologies from biotech, health tech, and the world of machine learning. Join us as DNA goes digital.
Join us to hear from a family whose child was diagnosed with a rare disease, before AI helped identify a treatment. Learn from the CEO of Retro Biosciences, a longevity and AI company that was backed by Sam Altman, and Marc Tessier-Lavigne, the veteran biotech executive who now runs Xaira, a closely watched company using AI to develop drugs. And find out what Anne Wojcicki has to say about how 23andMe has and hasn’t changed after its recent odyssey.
But also: Watch STAT’s Casey Ross lead a discussion on:
The promise and limits of AI in health care.
And, AI aside, catch biotech reporting legend Adam Feuerstein interviewing two of the biggest names in the drug industry: the CEOs of Insmed and BridgeBio, both big success stories. And be the first to see a list of the most innovative drug companies.
Anthropic is one of the co-sponsors of this event.
Aliza Apple, Ph.D.
VP of Catalyze360 AI/ML & Global Head of Lilly TuneLab, Eli Lilly and Company
Joe Betts-LaCroix
CEO, Retro Biosciences
Jonah Cool, Ph.D.
Head of Life Sciences Partnerships & Deployment, Anthropic
Anthony Costello
CEO, Medidata
Aleksey I. Gerasyuto, Ph.D.
Senior Vice President, Drug Discovery, Head of Chemistry, Schrödinger
Dave, Joanie, and Jorie Kraus
Lauren J. Kopsick
Founder & Executive Director, The Healthcare Navigation Project
Neil Kumar Ph.D.
Chief Executive Officer and Founder, BridgeBio Pharma, Inc.
William H. Lewis, J.D., M.B.A
Chair and Chief Executive Officer, Insmed
Ted W. Love, M.D.
Immediate Past Chair, BIO; Former CEO, GBT
Mohit Manrao
Senior Vice President, Head of US Oncology, AstraZeneca
Leslie Oley Wilberforce
Chief Executive Officer, Evidation
Jacqueline Poot
President, Strategic Consulting and Analytics, IDEA Pharma Business Unit, SAI MedPartners
Mark Sendak, M.D.
Co-Founder and CEO, Vega Health
Marc Tessier-Levigne, Ph.D.
Co-Founder, Chairman and CEO, Xaira Therapeutics
Whitney Thompson, M.D. M.Phil
Physician, Mayo Clinic
Anne Wojciciki
Founder and CEO, 23andMe Research Institute
Zachary Ziegler
Co-founder and CTO, OpenEvidence
–––-––––––––––––––––––––––––––––––––––––––––––––
Mario Aguilar MODERATOR
Health Tech Correspondent, STAT
Rick Berke MODERATOR
Co-founder & Executive Editor, STAT
Allison DeAngelis MODERATOR
Biotech Startups and Venture Capital Reporter, STAT
Adam Feuerstein MODERATOR
Senior Writer, Biotech, STAT
Damian Garde MODERATOR
Reporter at Large, Live and Feature Journalism, STAT
Matthew Herper MODERATOR
Senior Writer, Medicine, Editorial Director of Events, STAT
Lison Joseph MODERATOR
Health Tech Editor, STAT
Jesse McQuarters MODERATOR
Branded Content Editor, STAT
Katie Palmer MODERATOR
Health Tech Correspondent, STAT
Casey Ross MODERATOR
Chief Investigative Reporter, Data & Technology, STAT